Published in J Natl Cancer Inst on May 17, 1995
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol (1998) 3.23
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol (2011) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res (2008) 1.75
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A (1999) 1.56
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res (2010) 1.39
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res (2006) 1.35
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol (2010) 1.21
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer (1996) 1.12
The discovery and mechanism of action of letrozole. Breast Cancer Res Treat (2007) 1.04
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res (2009) 1.03
Long-range transcriptional control of progesterone receptor gene expression. Mol Endocrinol (2009) 1.03
A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer (2011) 1.02
Antiestrogens--tamoxifen, SERMs and beyond. Invest New Drugs (1999) 0.95
ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. Br J Cancer (2001) 0.95
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res (2011) 0.92
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J Med Chem (2010) 0.90
Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br J Cancer (1999) 0.90
Integration of endocrine therapy with targeted agents. Breast Cancer Res (2008) 0.88
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol (2014) 0.82
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer (2006) 0.82
Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer (2001) 0.82
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. Int J Cancer (2015) 0.82
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem (2010) 0.81
Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination. Breast Cancer Res Treat (2012) 0.81
The changing role of ER in endocrine resistance. Breast (2015) 0.80
Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents. Mini Rev Med Chem (2013) 0.80
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res (2004) 0.80
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.79
Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? Breast Cancer Res (2005) 0.79
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. BMC Cancer (2015) 0.79
Effects of psoralens as anti-tumoral agents in breast cancer cells. World J Clin Oncol (2014) 0.78
Synthesis and Pharmacological Evolution of Tetrahydroisoquinolines as Anti Breast Cancer Agents. J Cancer Sci Ther (2014) 0.78
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res (2016) 0.76
The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer (1997) 0.76
Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer. Int J Mol Sci (2016) 0.75
Antiestrogens: structure-activity relationships and use in breast cancer treatment. J Mol Endocrinol (2016) 0.75
Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. J Breast Cancer (2011) 0.75
The antiestrogens tamoxifen and fulvestrant abolish estrogenic impacts of 17α-ethinylestradiol on male calling behavior of Xenopus laevis. PLoS One (2012) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report. Case Rep Oncol (2009) 0.75
Neoadjuvant Endocrine Therapy in Breast Cancer. Breast Care (Basel) (2008) 0.75
Flexible Small Molecular Anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold Targets Multiple Estrogen Receptor Conformations. Cell Cycle (2017) 0.75
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med (1998) 6.86
Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med (1995) 3.88
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Risk of pulmonary complications after elective abdominal surgery. Chest (1996) 1.84
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet (1999) 1.76
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 1.62
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res (1997) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 1.53
Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer (1994) 1.51
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett (2005) 1.50
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat (2005) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics (2011) 1.40
Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med (2009) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med (1995) 1.34
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer (1986) 1.30
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology (2003) 1.29
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat (1994) 1.27
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res (1996) 1.26
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer (1994) 1.25
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer (1986) 1.24
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer (1987) 1.23
The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur J Cancer (1979) 1.23
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res (2001) 1.22
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab (1988) 1.22
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer (1979) 1.22
Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer (1993) 1.22
Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat (1999) 1.21
Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab (2004) 1.21
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer (1999) 1.20
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer (2006) 1.20
An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol (1999) 1.20
cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev (2000) 1.20
Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer (2005) 1.19
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol (1997) 1.17
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
Shipping stress and social status effects on pig performance, plasma cortisol, natural killer cell activity, and leukocyte numbers. J Anim Sci (1993) 1.15
E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer (2001) 1.15
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol (2009) 1.12
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer (2005) 1.12
Survival patterns in hormone treated advanced breast cancer. Br J Surg (1986) 1.12
A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl (1990) 1.11
AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene (2001) 1.10
Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst (1996) 1.10
The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol (1992) 1.10
Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer (1992) 1.10
Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. Br J Cancer (1989) 1.09
Measure once or twice -- does it really matter? J Natl Cancer Inst (1999) 1.09
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol (1988) 1.09
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol (1992) 1.09